CRISPR-enabled point-of-care genotyping for APOL1 genetic risk assessment

Abstract Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensit...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine 2024-09
Main Authors: Greensmith, Robert, Lape, Isadora T, Riella, Cristian V, Schubert, Alexander J, Metzger, Jakob J, Dighe, Anand S, Tan, Xiao, Hemmer, Bernhard, Rau, Josefine, Wendlinger, Sarah, Diederich, Nora, Schütz, Anja, Riella, Leonardo V, Kaminski, Michael M
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensitivity and specificity for point-of-care applications. While these methods have predominantly been used for pathogen sensing, their utilization for genotyping is limited. Here, we report a multiplexed CRISPR-based genotyping assay using LwaCas13a, PsmCas13b, and LbaCas12a, enabling the simultaneous detection of six genotypes. We applied this assay to identify genetic variants in the APOL1 gene prevalent among African Americans, which are associated with an 8–30-fold increase in the risk of developing kidney disease. Machine learning facilitated robust analysis across a multicenter clinical cohort of more than 100 patients, accurately identifying their genotypes. In addition, we optimized the readout using a multi-analyte lateral-flow assay demonstrating the ability for simplified genotype determination of clinical samples. Our CRISPR-based genotyping assay enables cost-effective point-of-care genetic variant detection due to its simplicity, versatility, and fast readout.
ISSN:1757-4684
1757-4684
DOI:10.1038/s44321-024-00126-x